Advertisement
News
Subscribe to Pharmaceutical Processing News

The Lead

AstraZeneca, MD Anderson Enter Collaboration to Help Improve Patient Outcomes in Ovarian/ Gynecologic Cancers

January 29, 2015 | Comments

AstraZeneca and The University of Texas MD Anderson Cancer Center today announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.

TOPICS:

FDA Approves IMBRUVICA for Treatment of Waldenstrom's Macroglobulinemia

January 29, 2015 12:54 pm | Comments

Pharmacyclics has announced that the FDA has granted single-agent IMBRUVICA (ibrutinib) regular (full) approval in all lines of therapy as the first and only treatment for patients with Waldenstrom's macroglobulinemia (WM), a rare, indolent type of B-cell lymphoma.

TOPICS:

Industry Group: Medical Device Tax Led to Thousands of Job Cuts

January 29, 2015 11:39 am | by Andrew Szal, Editor, Pharmaceutical Processing | Comments

The Advanced Medical Technology Association said the tax -- which was enacted as part of the Affordable Care Act to generate revenue for the law -- resulted in 4,500 job reductions in 2014.           

TOPICS:

California Declares Electronic Cigarettes a Health Threat

January 29, 2015 11:22 am | by FENIT NIRAPPIL, Associated Press | Comments

California health officials have declared electronic cigarettes a health threat that should be strictly regulated like tobacco products, joining other states and health advocates across the U.S. in seeking tighter controls as "vaping" grows in popularity.

TOPICS:
Advertisement

Vetter Completes Structural Work on New Multi-Functional Development Service and Information Technology Building

January 29, 2015 10:40 am | Comments

Following 16 months of construction, the first phase of a modern, multi-functional building at Vetter’s Ravensburg Schuetzenstrasse site has been completed. Estimated to be fully operational by the beginning of 2016, the new facility will contain high-tech laboratories and workplaces for Vetter Development Service, as well as a highly secure data center and additional office space for a total area of 8,500 sqm.

TOPICS:

WHO: Ebola Response Shifts to Ending Epidemic

January 29, 2015 8:40 am | by MARIA CHENG, AP Medical Writer | Comments

Health officials are now focused on ending the biggest-ever Ebola outbreak rather than just slowing the deadly virus' spread, the WHO said today. The U.N. health agency said the three most affected countries — Guinea, Sierra Leone and Liberia — have reported fewer than 100 cases in the past week, for the first time since June.

TOPICS:

Arizona Monitoring Hundreds for Measles Linked to Disneyland

January 29, 2015 8:36 am | by FELICIA FONSECA, Associated Press | Comments

A measles outbreak in Arizona that originated at California's Disney parks is at risk of increasing dramatically in size as health officials keep tabs on 1,000 people, including nearly 200 children who could have been exposed at a Phoenix-area medical center.

TOPICS:

Abbott Beats Fourth Quarter Profit Forecasts

January 29, 2015 8:29 am | Comments

Abbott Laboratories has reported fourth-quarter earnings of $905 million. On a per-share basis, the North Chicago, Illinois-based company said it had profit of 59 cents. Earnings, adjusted for one-time gains and costs, came to 71 cents per share.

TOPICS:

Vertex Fourth Quarter Loss Deeper Than Expected

January 29, 2015 8:25 am | Comments

Vertex Pharmaceuticals reported a wider-than-expected fourth-quarter loss but its revenue topped Wall Street's forecasts. Its stock fell $2.26, or almost 2 percent, to $119 in aftermarket trading.         

TOPICS:
Advertisement

Study: Insurers May Be Using Drug Costs to Discriminate

January 29, 2015 8:20 am | by KELLI KENNEDY, Associated Press | Comments

Insurance companies, perhaps more than previously thought, may be charging the sickest patients extra for drugs under the federal health law, in an effort to discourage them from choosing certain plans, according to a study released Wednesday. 

TOPICS:

Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global Collaboration to Develop Gene Therapies for Hemophilia

January 29, 2015 8:06 am | Comments

The agreement will combine San Raffaele - Telethon Institute for Gene Therapy’s (TIGET) extensive expertise in creating new gene therapy strategies and developing them from the bench to bedside with Biogen Idec’s deep understanding of hematology to potentially treat the underlying causes of hemophilia A and B.

TOPICS:

Alexion Appoints New Chief Executive Officer

January 29, 2015 8:02 am | Comments

Alexion Pharmaceuticals announced that its Board of Directors has appointed David L. Hallal as the Company’s Chief Executive Officer (CEO), effective April 1, 2015. Mr. Hallal currently serves as Alexion’s Chief Operating Officer (COO) and is a Director of the Board.

TOPICS:

3M In-home Needles Eligible for Clinical Trials

January 28, 2015 1:27 pm | by Andrew Szal, Editor, Pharmaceutical Processing | Comments

3M has announced its system of microscopic needles is now eligible for use in clinical trials. The Minnesota-based conglomerate's Hollow Microstructured Transdermal System aims to allow patients to receive injection prescription medications at home via a series of microneedles.

TOPICS:

American Glovebox Society Announces Annual Conference

January 28, 2015 11:39 am | Comments

The American Glovebox Society (AGS) Annual Conference will be held July 27-29, 2015 at the Town and Country Resort in San Diego.  The Conference features glovebox/isolator training with an emphasis on equipment integration including design - ergonomics - fabrication - safety - protection; interactive case study, technical sessions, exhibits, and more.

TOPICS:

Photo of the Day: Novartis CEO Joe Jimenez

January 28, 2015 11:16 am | by Mike Auerbach, Editor In Chief | Comments

It’s financial reporting season and the pharmaceutical industry is no exception. This week Novartis reported that its fourth quarter net income dropped a whopping 26% or “only” $1.49B compared to $2B from a year ago.      

TOPICS:

Tau-Based Vaccines Could Transform Early Alzheimer’s Disease Treatment, Says GlobalData Analyst

January 28, 2015 9:02 am | Comments

While current treatments for Alzheimer’s Disease (AD) are only able to ease symptoms temporarily, tau-based vaccines may offer a new and more effective way to treat AD in the early course of the disease, says an analyst with research and consulting firm GlobalData.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading